Ask My Investor AI
Public company · Frankfurt/XetraPublished company research
GXI

The issuer's share master-data page identifies Gerresheimer AG, ticker GXI, ISIN DE000A0LD6E6 and Frankfurt/Xetra listing; the FY2025 issuer release confirms the legal name, euro reporting and Düsseldorf, Germany issuer location.

Gerresheimer AG

Gerresheimer directly supplies primary pharmaceutical packaging and drug-delivery systems across 39 production sites. FY2025 revenue was EUR2.321B, including EUR983.5M in Primary Packaging Glass and EUR1.346B in Plastics & Devices. The review also identifies accounting corrections, negative net income, glass-demand weakness and site-level operating challenges; essential-medicine-only economics and current valuation remain unresolved.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
GXI
Exchange
Frankfurt/Xetra
HQ
Germany
Currency
EUR
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

The issuer reports a broad portfolio of vials, syringes, ampoules, cartridges, pens and auto-injectors produced across Europe, America and Asia. Scale and regulated manufacturing are supported, but the bounded evidence does not establish essential-medicine market share, switching costs or facility-level inspection status.

Scarce assets

Scarce assets in this value chain include validated sterile fill-finish lines and aseptic capacity, lyophilization (freeze-drying) capacity, aseptic quality systems and a clean fda inspection/warning-letter record.

Products, segments, and customers

FY2025 segments were Plastics & Devices, with EUR1.346B of revenue, and Primary Packaging Glass, with EUR983.5M. Products include vials, syringes, ampoules, cartridges, pens, auto-injectors and other primary packaging and delivery systems.

Theme capture

Direct containment and delivery capability and broad financial materiality are verified. The issuer does not isolate essential-medicine packaging economics; FY2025 also included accounting corrections and weaker Primary Packaging Glass demand and profitability.

Conditions

What must be true

  1. Obtain latest results and guidance; assess tubular/moulded glass capacity, GLP-1 exposure, and any take-private/PE interest.
  2. The exposure described for Gerresheimer must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Essential medicine manufacturing resilience brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Pharmaceutical primary-packaging and specialty glass supplier (vials, syringes, cartridges)

Essential medicine manufacturing resilience

Direct and financially material at the broad segment level: FY2025 Plastics & Devices revenue was EUR1.346B and Primary Packaging Glass revenue was EUR983.5M. Essential-medicine-specific packaging revenue and margins are not isolated.

Evidence
The issuer's audited FY2025 release directly supports its primary-packaging and drug-delivery portfolio, 39-site footprint, segment revenue and profitability. It also discloses accounting corrections, glass-demand weakness and operational challenges. Essential-medicine-only economics and facility inspection status are not disclosed.
Materiality
not assessed — Broad packaging and delivery segments are separately disclosed and material, but essential-medicine-specific revenue, orders and margins are not isolated; theme-specific materiality remains unassessed.
Financial evidence

Official public disclosures

Reference period: FY2025.

  • RevenueEUR2.321 billion
    FY2025[2]
  • Adjusted EBITDAEUR384.0 million
    FY2025[2]
  • Adjusted EBITDA margin16.8%
    FY2025[2]
  • Plastics & Devices revenueEUR1.346 billion
    FY2025[2]
  • Primary Packaging Glass revenueEUR983.5 million
    FY2025[2]
  • Primary Packaging Glass adjusted EBITDAEUR126.2 million
    FY2025[2]

Limitation: The figures cover broad packaging and delivery segments, not essential-medicine-specific economics. FY2025 statements include issuer-disclosed accounting corrections, and current market-derived valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • Procurement failure: GPOs and hospitals may keep rewarding lowest price rather than reliability, so validated capacity earns no durable premium (the primary thesis break).
  • GLP-1 concentration: a meaningful share of West and Stevanato growth is GLP-1-driven (~21-22% of Stevanato revenue); destocking or a shift to oral/alternative delivery could reverse it and blur the essential-medicine signal.

Thesis-break conditions

  • FDA/ASHP active sterile-injectable shortage counts fall sustainably toward pre-2020 lows (roughly sub-50 total active shortages) while procurement tenders remain price-only, indicating reliability is not being rewarded.
  • Aggregate sterile fill-finish and containment capacity additions outpace demand, evidenced by falling capacity utilization and softening pricing/mix at West, Stevanato and Gerresheimer over consecutive quarters.
Investability conclusion

Where the evidence lands

Official FY2025 evidence verifies a scaled pharmaceutical packaging and delivery platform, while also showing accounting corrections, negative net income and weaker Primary Packaging Glass demand and margins. Essential-medicine-specific economics, facility inspection status and licensed current valuation remain unresolved. No reviewer has accepted the subject; it remains NOT_READY.

Next diligence

  1. Obtain latest results and guidance; assess tubular/moulded glass capacity, GLP-1 exposure, and any take-private/PE interest.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Gerresheimer share master dataGerresheimer AG · primary · published undated · accessed 2026-07-29
  2. Gerresheimer publishes 2025 annual and consolidated financial statementsGerresheimer AG · primary · published 2026-06-29 · accessed 2026-07-29